Alvotech Expands its Board of Directors as part of Transition from Private to Publicly Traded Company

2 years ago

Four new members enhance independence and diversity of Board of DirectorsAlvotech is dual listed on NASDAQ in the U.S. and…

InspireMD Announces Appointment of Endovascular Pioneer Dr. Juan Parodi as Strategic Advisor

2 years ago

Credited with performing the first ever endovascular repair procedure in 1990TEL AVIV, Israel, July 14, 2022 (GLOBE NEWSWIRE) -- InspireMD,…

Completion of AffinityDNA Acquisition expanding global direct-to-consumer business

2 years ago

MELBOURNE, Australia, July 14, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader…

Pasithea Therapeutics Awarded a Drug Development Research Grant

2 years ago

-- AUD $1 million (U.S $694,000) grant transferred as part of Alpha-5 Integrin, LLC transaction ---- Provides approximately U.S. $694,000…

Alvotech Expands its Board of Directors as part of Transition from Private to Publicly Traded Company

2 years ago

Four new members enhance independence and diversity of Board of DirectorsAlvotech (NASDAQ and First North Growth Market: ALVO), a global…

Revolo Biotherapeutics Awarded Innovation Passport for ‘1805 in the United Kingdom for the Treatment of Moderate to Severe Rheumatoid Arthritis

2 years ago

NEW ORLEANS and LONDON, July 14, 2022 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a company developing…

Cocrystal Pharma Reports CC-42344 Pharmacokinetic Data in Influenza A Once-Daily Dosing

2 years ago

Single Ascending Dose Portion of Phase 1 Study Completed BOTHELL, Wash., July 14, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq:…

TFF Pharmaceuticals Expands R&D Operations with New Austin Facility

2 years ago

New Facility in Austin Will Enable Increased Capacity for Internal Pipeline Assets While Accommodating Growing Interest in Partnered Projects Significantly…

Rubius Therapeutics Appoints Susanne Schaffert, Ph.D., to its Board of Directors

2 years ago

CAMBRIDGE, Mass., July 14, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically…

Theratechnologies Reports Second Quarter and First Half Fiscal 2022 Financial Results and Provides Business Update

2 years ago

– Q2 2022 Consolidated Sales Growth of 8.3% to $19.3 million – Year-to-Date Revenue Growth of 13.9% or $37.8 million…